Melanoma

Regional Health is involved in melanoma research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.


S1320
Randomized Phase II Trial of Intermittent vs Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology

 

 

S1616:
Randomized Phase II Trial of Intermittent vs Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology